Trial Profile
Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Sep 2022 Status changed from active, no longer recruiting to completed.
- 02 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2017 New trial record